Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Related keylists
Walvax Biotechnology Co Ltd (Walvax) is a biotechnology company that carries out the research, development, manufacturing, and distribution of vaccines. The company's pipeline products include vaccines such as recombinant 9-valent HPV vaccine, Group ACYW135 meningococcal polysaccharide conjugate vaccine, tetanus vaccine, 20-valent pneumococcal polysaccharide conjugate vaccine, SARS-CoV-2 mRNA vaccine, and SARS-CoV-2 mRNA vaccine. Walvax's products are utilized in the healthcare industry to protect against various infectious diseases. The company operates in China, Indonesia, Thailand, and the US. Walvax is headquartered in Kunming, Yunnan Province, China.
Headquarters
China
Address
No. 395, Kexin Road, High-Tech Zone, Kunming, Yunnan, 650101
Website
www.walvax.com
Telephone
86 871 68312779
No of Employees
1,981
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
300142 (SHE)
Revenue (2024)
$336.5M
-14.3%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
25%
(2024 vs 2023)
Market Cap*
$3.1B
Net Profit Margin (2024)
XYZ
45.8%
(2024 vs 2023)
* As of and is in US$
Walvax Biotechnology Co Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| 9-Valent HPV Vaccine | Walvax |
| ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine | |
| COVID-19 Variant Mrna Vaccine (S Protein Chimera) | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Contracts/Agreements | In November, the company partnered with Mirxes Holding Company Limited to develop an RNA-centric preventive and precision medicine platform. |
| 2022 | Contracts/Agreements | In November, the company signed an agreement with Etana to localize PCV and HPV vaccines in Indonesia, expanding their collaboration beyond the SARS-CoV-2 mRNA vaccine. |
| 2021 | Contracts/Agreements | In April, the company and Sirnaomics Biopharmaceuticals entered into a partnership agreement to co-develop its Antiviral RNAi therapeutic product candidate STP702. |
Competitor Comparison
| Key Parameters | Walvax Biotechnology Co Ltd | Hainan Haiyao Co Ltd | Beijing SL Pharmaceutical Co Ltd | BioStar Pharmaceuticals Inc |
|---|---|---|---|---|
| Headquarters | China | China | China | China |
| City | Kunming | Haikou | Beijing | Xianyang |
| State/Province | Yunnan | Hainan | Beijing | Shaanxi |
| No. of Employees | 1,981 | 1,738 | 901 | - |
| Entity Type | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Li Yunchun | Chairman | Executive Board | 2009 | 64 |
| Dong Shaozhong | Vice Chairman | Executive Board | 2022 | 58 |
| Yao Wei | President; Director | Executive Board | 2026 | 54 |
| Sun Mingbo | Director; Vice President | Executive Board | 2026 | 57 |
| Wu Changxiong | Chief Financial Officer | Senior Management | 2024 | 43 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer